Inflammatory Disorders with Unique Clinical Features

  • Kelli D. Grim
  • Ted Rosen


This chapter reviews the differential diagnosis, histopathology, treatment, etiology, epidemiology, laboratory studies, and pathophysiology of a number of inflammatory disorders with unique clinical features and their particular manifestations in skin of color. Among these disorders are atopic dermatitis, lichen planus, lupus erythematosus, pityriasis rosea, psoriasis, sarcoidosis, scleroderma, seborrheic dermatitis, syphilis, tinea versicolor, and white spot parapsoriasis.


Atopic Dermatitis Lichen Planus Erythema Nodosum Seborrheic Dermatitis Oral Lichen Planus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Rosen T, Orengo IF, Koff AB, Schell BJ. Clinical dermatology in black patients. Bari: Pigreco; 1995.Google Scholar
  2. 2.
    Wasserbauer N, Ballow M. Atopic dermatitis. Am J Med. 2009;122:121–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Nnoruka EN. Current epidemiology of atopic dermatitis in South-Eastern Nigeria. Int J Dermatol. 2004;43:739–44.PubMedCrossRefGoogle Scholar
  4. 4.
    Dhar S, Kanwar AJ. Epidemiology and clinical pattern of atopic dermatitis in a North Indian pediatric population. Pediatr Dermatol. 1998;15:347–51.PubMedCrossRefGoogle Scholar
  5. 5.
    Lee HJ, Cho SH, Ha SJ, et al. Minor cutaneous features of atopic dermatitis in South Korea. Int J Dermatol. 2000;39:337–42.PubMedCrossRefGoogle Scholar
  6. 6.
    Allen HB, Jones NP, Bowen SE. Lichenoid and other clinical presentations of atopic dermatitis in an inner city practice. J Am Acad Dermatol. 2008;58:503–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Summey BT, Bowen SE, Allen HB. Lichen planus-like atopic dermatitis: expanding the differential diagnosis of spongiotic dermatitis. J Cutan Pathol. 2008;35:311–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Ben-Gashir MA, Hay RJ. Reliance on erythema scores may mask severe atopic dermatitis in black children compared with their white counterparts. Br J Dermatol. 2002;147:920–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Schachner L, Ling NS, Press S. A statistical analysis of a pediatric dermatology clinic. Pediatr Dermatol. 1983;1:157–64.PubMedCrossRefGoogle Scholar
  10. 10.
    Lee CS, Lim HW. Cutaneous diseases in Asians. Dermatol Clin. 2003;21:669–77.PubMedCrossRefGoogle Scholar
  11. 11.
    Bonness S, Bieber T. Molecular basis of atopic dermatitis. Curr Opin Allergy Clin Immunol. 2007;7:382–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Allam JP, Novak N. The pathophysiology of atopic eczema. Clin Exp Dermatol. 2006;31:89–93.PubMedCrossRefGoogle Scholar
  13. 13.
    Peterson JD, Chan LS. A comprehensive management guide for atopic dermatitis. Dermatol Nurs. 2006;18:531–42.PubMedGoogle Scholar
  14. 14.
    Katta R. Lichen planus. Am Fam Physician. 2000;61:3319–24.PubMedGoogle Scholar
  15. 15.
    Ellgehausen P, Elsner P, Burg G. Drug-induced lichen planus. Clin Dermatol. 1998;16:325–32.PubMedCrossRefGoogle Scholar
  16. 16.
    Nnoruka EN. Lichen planus in African children: a study of 13 patients. Pediatr Dermatol. 2007;24:495–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Marshman G. Lichen planus. Australas J Dermatol. 1998;39:1–11.PubMedCrossRefGoogle Scholar
  18. 18.
    Boyd AS. New and emerging therapies for lichenoid dermatoses. Dermatol Clin. 2000;18:21–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol. 2002;46:207–14.PubMedCrossRefGoogle Scholar
  20. 20.
    Alam F, Hamburger J. Oral mucosal lichen planus in children. Int J Paediatr Dent. 2001;11:209–14.PubMedCrossRefGoogle Scholar
  21. 21.
    Sontheimer RD. Lichenoid tissue reaction/interface dermatitis: clinical and histological ­perspectives. J Invest Dermatol. 2009;129:1088–99.PubMedCrossRefGoogle Scholar
  22. 22.
    Nagao Y, Sata M. Hepatitis C virus and lichen planus. J Gastroenterol Hepatol. 2004;19:1101–13.PubMedCrossRefGoogle Scholar
  23. 23.
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25: 1271–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.PubMedCrossRefGoogle Scholar
  25. 25.
    McCauliffe DP. Cutaneous lupus erythematosus. Semin Cutan Med Surg. 2001;20:14–26.PubMedCrossRefGoogle Scholar
  26. 26.
    Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol. 2006;24:348–62.PubMedCrossRefGoogle Scholar
  27. 27.
    Martin S, Rosen T, Locker E. Metastatic squamous cell carcinoma of the lip. Occurrence in blacks with discoid lupus erythematosus. Arch Dermatol. 1979;115:1214.PubMedCrossRefGoogle Scholar
  28. 28.
    Fabbri P, Cardinali C, Giomi B, et al. Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol. 2003;4:449–65.PubMedCrossRefGoogle Scholar
  29. 29.
    Tikly M, Burgin S, Mohanlal P, Bellingan A, George J. Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations. Clin Rheumatol. 1996;15:261–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Nath SK, Namjou B, Kilpatrick J, et al. A candidate region on 11p13 for systemic lupus erythematosus: a linkage identified in African-American families. J Investig Dermatol Symp Proc. 2004;9:64–7.PubMedCrossRefGoogle Scholar
  31. 31.
    González LM, Allen R, Janniger CK, Schwartz RA. Pityriasis rosea: an important papulosquamous disorder. Int J Dermatol. 2005;44:757–64.PubMedCrossRefGoogle Scholar
  32. 32.
    Stulberg DL, Wolfrey J. Pityriasis rosea. Am Fam Physician. 2004;69:87–91.PubMedGoogle Scholar
  33. 33.
    Amer A, Fischer H, Li X. The natural history of pityriasis rosea in black American children: how correct is the “classic” description? Arch Pediatr Adolesc Med. 2007;161:503–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Chuh A, Chan H, Zawar V. Pityriasis rosea–evidence for and against an infectious aetiology. Epidemiol Infect. 2004;132:381–90.PubMedCrossRefGoogle Scholar
  35. 35.
    Kempf W, Burg G. Pityriasis rosea–a virus-induced skin disease? An update. Arch Virol. 2000;145:1509–20.PubMedCrossRefGoogle Scholar
  36. 36.
    Canpolat Kirac B, Adisen E, Bozdayi G, Yucel A, Fidan I, Aksakal N, et al. The role of human herpesvirus 6, human herpesvirus 7, Epstein-Barr virus and cytomegalovirus in the aetiology of pityriasis rosea. J Eur Acad Dermatol Venereol. 2009;23:16–21.PubMedCrossRefGoogle Scholar
  37. 37.
    Wolff K, Johnson RA. Psoriasis. In: Sydor AM, Englis MR, editors. Fitzpatrick’s color atlas and synopsis of clinical dermatology. 6th ed. New York: McGraw-Hill; 2009. p. 53–71.Google Scholar
  38. 38.
    Leder RO, Farber EM. The variable incidence of psoriasis in sub-Saharan Africa. Int J Dermatol. 1997;36:911–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Kormeili T, Lowe NJ, Yamauchi PS. Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences. Br J Dermatol. 2004;151:3–15.PubMedCrossRefGoogle Scholar
  40. 40.
    Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005;52:23–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Nograles KE, Brasington RD, Bowcock AM. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol. 2009;5:83–91.PubMedCrossRefGoogle Scholar
  42. 42.
    Nickoloff BJ, Qin JZ, Nestle FO. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol. 2007;33:45–56.PubMedCrossRefGoogle Scholar
  43. 43.
    Gottlieb AB. Therapeutic options in the treatment of psoriasis and atopic dermatitis. J Am Acad Dermatol. 2005;53:S3–16.PubMedCrossRefGoogle Scholar
  44. 44.
    Lebwohl M. A clinician’s paradigm in the treatment of psoriasis. J Am Acad Dermatol. 2005;53:S59–69.PubMedCrossRefGoogle Scholar
  45. 45.
    Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs. 2008;68: 1361–83.PubMedCrossRefGoogle Scholar
  46. 46.
    Tchernev G. Cutaneous sarcoidosis: the “great imitator”: etiopathogenesis, morphology, ­differential diagnosis, and clinical management. Am J Clin Dermatol. 2006;7:375–82.PubMedCrossRefGoogle Scholar
  47. 47.
    Katta R. Cutaneous sarcoidosis: a dermatologic masquerader. Am Fam Physician. 2002;65:1581–4.PubMedGoogle Scholar
  48. 48.
    Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997;336:1224–34.PubMedCrossRefGoogle Scholar
  49. 49.
    Fernandez-Faith E, McDonnell J. Cutaneous sarcoidosis: differential diagnosis. Clin Dermatol. 2007;25:276–87.PubMedCrossRefGoogle Scholar
  50. 50.
    Jacyk WK. Cutaneous sarcoidosis in black South Africans. Int J Dermatol. 1999;38:841–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Chong WS, Tan HH, Tan SH. Cutaneous sarcoidosis in Asians: a report of 25 patients from Singapore. Clin Exp Dermatol. 2005;30:120–4.PubMedCrossRefGoogle Scholar
  52. 52.
    Costabel U, Guzman J, Baughman RP. Systemic evaluation of a potential cutaneous sarcoidosis patient. Clin Dermatol. 2007;25:303–11.PubMedCrossRefGoogle Scholar
  53. 53.
    Ahmed I, Harshad SR. Subcutaneous sarcoidosis: is it a specific subset of cutaneous sarcoidosis frequently associated with systemic disease? J Am Acad Dermatol. 2006;54:55–60.PubMedCrossRefGoogle Scholar
  54. 54.
    Chen ES, Moller DR. Etiology of sarcoidosis. Clin Chest Med. 2008;29:365–77.PubMedCrossRefGoogle Scholar
  55. 55.
    Marcoval J, Moreno A, Mañá J, Peyri J. Subcutaneous sarcoidosis. Dermatol Clin. 2008;26:553–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Katta R, Nelson B, Chen D, Roenigk H. Sarcoidosis of the scalp: a case series and review of the literature. J Am Acad Dermatol. 2000;42:690–2.PubMedGoogle Scholar
  57. 57.
    Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360:1989–2003.PubMedCrossRefGoogle Scholar
  58. 58.
    Zhou X, Tan FK, Wang N, Xiong M, Maghidman S, Reveille JD, et al. Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum. 2003;48:2585–92.PubMedCrossRefGoogle Scholar
  59. 59.
    Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35:35–42.PubMedCrossRefGoogle Scholar
  60. 60.
    Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23:581–90Google Scholar
  61. 61.
    Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc. 1995;70:1068–76.PubMedCrossRefGoogle Scholar
  62. 62.
    Costner MI, Grau RH. Update on connective tissue diseases in dermatology. Semin Cutan Med Surg. 2006;25:207–20.PubMedCrossRefGoogle Scholar
  63. 63.
    Mayes MD. Classification and epidemiology of scleroderma. Semin Cutan Med Surg. 1998;17:22–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Nietert PJ, Mitchell HC, Bolster MB, Shaftman SR, Tilley BC, Silver RM. Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol. 2006;33:263–8.PubMedGoogle Scholar
  65. 65.
    Sontheimer RD. Skin manifestations of systemic autoimmune connective tissue disease: diagnostics and therapeutics. Best Pract Res Clin Rheumatol. 2004;18:429–62.PubMedGoogle Scholar
  66. 66.
    Halder RM, Roberts CI, Nootheti PK. Cutaneous diseases in the black races. Dermatol Clin. 2003;21:679–87.PubMedCrossRefGoogle Scholar
  67. 67.
    Steen VD. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg. 1998;17:48–54.PubMedCrossRefGoogle Scholar
  68. 68.
    Ee HL, Tan SH. Reticulate hyperpigmented scleroderma: a new pigmentary manifestation. Clin Exp Dermatol. 2005;30:131–3.PubMedCrossRefGoogle Scholar
  69. 69.
    Adelowo OO, Oguntona S. Scleroderma (systemic sclerosis) among Nigerians. Clin Rheumatol. 2009;28:1121–5.PubMedCrossRefGoogle Scholar
  70. 70.
    Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum. 2001;30:332–46.PubMedCrossRefGoogle Scholar
  71. 71.
    Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger Jr TA, Wright TM. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum. 1999;42:465–74.PubMedCrossRefGoogle Scholar
  72. 72.
    Mayes MD, Lacey Jr JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48:2246–55.PubMedCrossRefGoogle Scholar
  73. 73.
    Steen VD, Oddis CV, Conte CG, Janoski J, Casterline GZ, Medsger Jr TA. Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963–1982. Arthritis Rheum. 1997;40:441–5.PubMedCrossRefGoogle Scholar
  74. 74.
    Tamaki T, Mori S, Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res. 1991;283:366–71.PubMedCrossRefGoogle Scholar
  75. 75.
    Reveille JD. Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Rep. 2003;5:160–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger Jr TA. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum. 2009;60:1112–8.PubMedCrossRefGoogle Scholar
  77. 77.
    Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest. 1998;114:801–7.PubMedCrossRefGoogle Scholar
  78. 78.
    White B. Clinical approach to scleroderma. Semin Cutan Med Surg. 1998;17:213–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Pope JE, Shum DT, Gottschalk R, Stevens A, McManus R. Increased pigmentation in scleroderma. J Rheumatol. 1996;23:1912–6.PubMedGoogle Scholar
  80. 80.
    Gupta AK, Batra R, Bluhm R, Boekhout T, Dawson Jr TL. Skin diseases associated with Malassezia species. J Am Acad Dermatol. 2004;51:785–98.PubMedCrossRefGoogle Scholar
  81. 81.
    Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician. 2006;74:125–30.PubMedGoogle Scholar
  82. 82.
    Johnson BA, Nunley JR. Treatment of seborrheic dermatitis. Am Fam Physician. 2000;61(2703–2710):2713–4.Google Scholar
  83. 83.
    Gupta AK, Nicol KA. Seborrheic dermatitis of the scalp: etiology and treatment. J Drugs Dermatol. 2004;3:155–8.PubMedGoogle Scholar
  84. 84.
    Halder RM, Nootheti PK. Ethnic skin disorders overview. J Am Acad Dermatol. 2003;48:S143–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Ogunbiyi AO, Daramola OO, Alese OO. Prevalence of skin diseases in Ibadan, Nigeria. Int J Dermatol. 2004;43:31–6.PubMedCrossRefGoogle Scholar
  86. 86.
    Gupta AK, Madzia SE, Batra R. Etiology and management of Seborrheic dermatitis. Dermatology. 2004;208:89–93.PubMedCrossRefGoogle Scholar
  87. 87.
    Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol. 2000;1:75–80.PubMedCrossRefGoogle Scholar
  88. 88.
    Brown DL, Frank JE. Diagnosis and management of syphilis. Am Fam Physician. 2003;68:283–90.PubMedGoogle Scholar
  89. 89.
    Lautenschlager S. Cutaneous manifestations of syphilis: recognition and management. Am J Clin Dermatol. 2006;7:291–304.PubMedCrossRefGoogle Scholar
  90. 90.
    Rosen T, Hwong H. Pedal interdigital condylomata lata: a rare sign of secondary syphilis. Sex Transm Dis. 2001;28:184–6.PubMedCrossRefGoogle Scholar
  91. 91.
    Kent ME, Romanelli F. Reexamining syphilis: an update on epidemiology, clinical manifestations, and management. Ann Pharmacother. 2008;42:226–36.PubMedCrossRefGoogle Scholar
  92. 92.
    Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, 2007. Atlanta: U.S. Department of Health and Human Services; 2008.Google Scholar
  93. 93.
    Singh AE, Romanowski B. Syphilis: review with emphasis on clinical, epidemiologic, and some biologic features. Clin Microbiol Rev. 1999;12:187–209.PubMedGoogle Scholar
  94. 94.
    Zetola NM, Klausner JD. Syphilis and HIV infection: an update. Clin Infect Dis. 2007;44:1222–8.PubMedCrossRefGoogle Scholar
  95. 95.
    Sunenshine PJ, Schwartz RA, Janniger CK. Tinea versicolor. Int J Dermatol. 1998;37:648–55.PubMedCrossRefGoogle Scholar
  96. 96.
    Crespo-Erchiga V, Florencio VD. Malassezia yeasts and pityriasis versicolor. Curr Opin Infect Dis. 2006;19:139–47.PubMedCrossRefGoogle Scholar
  97. 97.
    Mollet I, Ongenae K, Naeyaert JM. Origin, clinical presentation, and diagnosis of hypomelanotic skin disorders. Dermatol Clin. 2007;25:363–71.PubMedCrossRefGoogle Scholar
  98. 98.
    Gupta AK, Batra R, Bluhm R, Faergemann J. Pityriasis versicolor. Dermatol Clin. 2003;21:413–29.PubMedCrossRefGoogle Scholar
  99. 99.
    Aljabre SH, Alzayir AA, Abdulghani M, Osman OO. Pigmentary changes of tinea versicolor in dark-skinned patients. Int J Dermatol. 2001;40:273–5.PubMedCrossRefGoogle Scholar
  100. 100.
    Elewski BE, Abramovits W, Kempers S, Schlessinger J, Rosen T, Gupta AK, Abraham S, Rowell R. A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. J Drugs Dermatol. 2007;6:1001–8.PubMedGoogle Scholar
  101. 101.
    Warin AP. Hypochromic variant of pityriasis lichenoides chronic. Clin Exp Dermatol. 1978;3:85–7.PubMedCrossRefGoogle Scholar
  102. 102.
    Clayton R, Warin A. Pityriasis lichenoides chronic presenting as hypopigmentation. Br J Dermatol. 1979;100:297–302.PubMedCrossRefGoogle Scholar
  103. 103.
    Guillet G, Helenon R, Gauthier Y, Surleve-Bazeille JE, Plantin P, Sassolas BP. Progressive macular hypomelanosis of the trunk: primary acquired hypopigmentation. J Cutan Pathol. 1988;15:286–9.PubMedCrossRefGoogle Scholar
  104. 104.
    MacKee GM, Wise W. White spot disease. J Cutan Dis. 1914;32:629–60.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of DermatologyTulane University Health Science CenterNew OrleansUSA
  2. 2.Department of DermatologyBaylor College of MedicineHoustonUSA

Personalised recommendations